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Abstract: 
Objective: The aim of this study was to: (i) screen a large group of unselected 
patients with juvenile systemic lupus erythematosus for anti-aquaporin 4 
antibodies (AQP4-Ab); (ii) identify clinical and laboratory predictors of presence 
of AQP4-Ab positivity in jSLE. 
Methods: Sera from ninety patients with jSLE were tested for the presence of 
AQP4-Ab using a cell-based assay. Demographics, clinical and immunological 
features, treatment received were summarized. Fisher’s exact test was used to 
identify clinical predictors of positivity for AQP4-Ab. 
Results: Five of 90 (5.5%) patients tested positive for AQP4-Ab, all of which 
had neurological involvement, mainly transverse myelitis and optic neuritis. 
AQP4-Ab positive patients were more likely to have neurological symptoms 
(p=0.002), less likely to experience dermatological manifestations (p=0.045), 
and less likely to have detectable anti-dsDNA antibodies (p=0.022). These 
patients were also more likely to have received anti-epileptic (p=0.023) and 
anti-coagulant (p=0.007) drugs. 
Conclusions: The findings of this study indicate that some patients with jSLE 
develop antibodies against AQP4 and may be at risk of developing a 
neurological clinical phenotype. We suggest that all jSLE patients should be 
systematically screened for presence of AQP4-Ab and this may help identify a 
high risk  for neurological involvement in jSLE. 
 
Introduction 
Aquaporin-4 (AQP4) is a water channel found on the foot processes of 
astrocyte cells in the brain and is also expressed in the renal tract, the 
gastrointestinal system, skeletal muscles, lung and blood system [1,2].  
In the central nervous system, AQP4 are involved in water movement, cell 
migration and neuroexcitation [3]. Antibodies are predominantly of the IgG1 
subtype and bind three-dimensional conformational epitopes on the 
extracellular loops of AQP4. This produces astrocyte damage by complement-
dependent cytotoxicity which leads to blood–brain barrier disruption and cause 
leukocyte infiltration and cytokine release resulting in damage to 
oligodendrocyte, myelin and neurons [3]. 
 
Antibodies against AQP4 (AQP4-Ab) were first identified in 2005 in patients 
with neuroinflammation best now classified as having neuromyelitis optica 
spectrum disorders (NMOSD) [1]. These NMOSD are a group of inflammatory 
disorders of the central nervous system that often present with a relapsing 
remitting course and are characterized by optic neuritis and longitudinally 
extensive transverse myelitis (LETM). They are typically associated with serum 
antibodies that selectively bind to AQP4 or myelin oligodendrocyte glycoprotein 
2 (MOG) [1].  
 
The discovery of pathogenic AQP4-Ab resulted in expansion of the clinical 
phenotypes associated with NMSOD to include patients with more atypical 
neuroinflammation even in the absence of optic neuritis and transverse myelitis 
but who test positive for these antibodies. Notably, in recent years, growing 
evidence suggests that AQP4-IgG may also causes damage to peripheral 
AQP4-expressing organs beyond the CNS such as skeletal muscle, 
vestibulocochlear nerves, gastrointestinal tract, blood system, kidney, lung and 
placenta [2]. So the spectrum of disease associated with these autoantibodies 
may expand over the years.  
 
Notably, the presence of AQP4-Ab has already been described in the context 
of systemic autoimmune diseases such as adult onset systemic lupus 
erythematosus (SLE) [4,5,6] but no studies have systematically assessed the 
presence of AQP4-Ab in children and adolescents with juvenile onset SLE 
(jSLE). While jSLE shares clinical and serological features with adult-onset 
SLE, jSLE typically exhibits a much more severe protracted disease course. 
Notably the incidence of neuropsychiatric manifestations in jSLE is much more 
common than in adult patients [7]. Whether this increased frequency of 
neurological manifestations in paediatric patients relates to the presence of 
neurotoxic antibodies such as AQP4-Ab remains unclear. 
 
The aim of this study was therefore to: (i) screen a large group of unselected 
patients with jSLE for AQP4-Ab; (ii) identify clinical and laboratory predictors of 
presence of AQP4-Ab positivity in jSLE. 
 
 
Methods 
We screened for the presence of AQP4-Ab a total of 90 patients with jSLE 
fulfilling the 1997 American College of Rheumatology (ACR) criteria  [8]  seen 
in the Paediatric and Adolescent Rheumatology and Paediatric Neurology 
departments at Great Ormond Street Hospital for Children NHS Foundation 
Trust and University College London Hospitals between 2009 and 2017. Ethical 
approval for the study was obtained from the Regional Ethical Committee 
(Study reference 16IR33). 
AQP4-IgG antibodies were measured in serum using a validated commercially 
available cell-based assay (Euroimmun, United Kingdom) as per 
manufacturer’s instructions [9]. In addition, testing for MOG antibodies was also 
completed for those patients with positive AQP4-Ab.  
 
The demographic, clinical, and laboratory characteristics recorded were as 
follows: sex, age, ethnicity (established via the information provided by 
patients/parents to register with the hospital), neurological symptoms, previous 
organ involvement, manifestations of jSLE, erythrocyte sedimentation rate 
(ESR, in the first hour; normal <10 mm/h) and serum C-reactive protein (CRP; 
normal range < 10 mg/L), presence of anti-dsDNA antibodies (normal range 0–
9.9 IU/ml), anti-nuclear antibodies (ANA), antibodies to extractable nuclear 
antigens (ENA) and its subtypes, antiphospholipid antibodies (ACL), lupus 
anticoagulant (LA), and complement C3 and C4 levels. Therapies used were 
also recorded. 
 
Statistical analysis was performed using SPSS (SPSS Inc., Chicago, IL, USA). 
Fisher’s exact test was used for comparison between groups. Categorical data 
were summarised as percentages. Any continuous variables were summarised 
as median and range. 2-sided p-values less than 0.05 were considered 
significant. 
 Results 
We studied a total of 90 patients (11/90, 12% male) with jSLE with a median 
age of 18.7 (range 11 to 27) years old. Nineteen/90 (21%) were White British, 
11/90 (12%) White Other, 3/90 (3%) Black British, 7/90 (8%) Black African, 
11/90 (12%) Black Caribbean, 24/90 (27%) Asian, 15/90 (17%) of mixed 
background or of other or unknown ethnicity. The median age of disease onset 
was 8 (range 0.3 –15) years old.   
Five/90 patients tested positive for AQP4-Ab. All patients but one who tested 
positive for AQP4-IgG at diagnosis remained positive on repeat measurements 
during follow up: median 3 measurements (range 1-8) over a median of 18.5 
months (range 9-20 months). 
Table 1 summarises the clinical characteristics of the 5 patients who tested 
positive for AQP4-Ab at the time of initial presentation and latest follow up, brain 
magnetic resonance (MRI) imaging findings and treatment received. These 5 
patients had a median age of 15 (range 11-17.5) years old; a median disease 
duration of 3 (range 0.2 - 8.5) years, and a median length of follow up of 3 
(range 1- 9) years.   
Predominant neurological presentation was observed in 3/5 (60%) at onset with 
the other two developing neurological symptoms over time. Four/5 (80%) 
patients fulfilled the diagnostic criteria for NMOSD (table 2, supplementary 
material) [10]. MOG antibodies tested negative in 5/5 patients. Two/4 patients 
with spinal lesions had recurrence of transverse myelitis and optic neuritis in 
more than one occasion (Figure 1). One child presented with acute psychosis, 
in context of normal neuroimaging.  Cerebrospinal fluid analysis was performed 
in two patients. CSF was acellular, with normal protein and no detection of CSF 
oligoclonal bands.  
Treatment received included corticosteroids in all patients; cyclophosphamide 
(2/5); rituximab (3/5); plasma exchange (2/5); azathioprine (3/5); and 
mycophenolate mofetil (MMF) (2/5). 
 
Predictors of presence of AQP4-Ab in jSLE 
Patients with positive AQP4-Ab were more likely to have neurological 
involvement compared to those who tested negative, (p=0.002), and they were 
less likely to have skin involvement (p=0.045) (Table 3). There appeared to be 
no other significant differences between groups of patients when the remaining 
clinical features were considered.  
Patients with positive AQP4-Ab were less likely to have positive anti-dsDNA 
antibodies than those with negative AQP4-Ab (p=0.022) (Table 3), with no other 
significant differences between the two groups of patients when the remaining 
laboratory characteristics were considered. 
All treatments received prior to the sample collection were included in the 
analysis.  Patients with AQP4-Ab antibodies were more likely to receive anti-
epileptics (p=0.023), and anti-coagulants (p=0.007), and they were less likely 
to have received hydroxychloroquine (p<0.001) (Table 3). 
 
Discussion 
In this retrospective case series, we have shown that there is a subgroup of 
patients with jSLE that develop AQP4-Ab and these patients are more likely to 
develop neurological involvement. The main clinical phenotype associated with 
AQP4-IgG seropositivity was transverse myelitis and optic neuritis. We would 
recommend that clinicians have a low threshold for screening for presence of 
these antibodies in patients with jSLE and have a low threshold for undertaking 
neuroimaging investigations to screen for neurological involvement.  
 
A previous study in adults with SLE that systematically assessed for the 
presence of anti AQP4-IgG antibodies in a large cohort of patients, indicated 
that only SLE patients with NMOSD features tested positive for these antibodies 
[4]. These results therefore were supportive of the specificity of a positive test 
for AQP4-Ab rather than this being an epiphenomenon of autoimmunity, and 
were highlighting a unique neurological clinical phenotype in SLE. We now also 
demonstrate that younger patients with jSLE may also develop these antibodies 
and are also at risk of neurological involvement.  
 
We note the lack of classical NMOSD clinical features in one patient positive 
for AQP4-Ab. This patient however had already received significant 
immunosuppressive treatment for other jSLE features at the time of AQP4-Ab 
testing, which may have influenced his clinical presentation.  Although false 
positivity cannot be ruled out, it is possible that NMOSD symptomatology may 
differ in patients with established autoimmunity. Alternatively, antibody positivity 
may precede the onset of severe neurological phenotype similar to reports in 
case of patients with myasthenia gravis [11].  
 
The therapeutic approach with respects to immunosuppression did not differ 
between groups and this is unsurprising as rituximab, cyclophosphamide and 
corticosteroids are effective therapies for NMOSD as well as SLE. The patients 
with AQP4-Ab positive were less likely to be treated with HCQ. Although HCQ 
is a safe drug and generally recommended for the treatment of all patients with 
SLE [12], the decreased use in the patients with AQP4-Ab positivity could 
reflect the reluctance of the clinicians to add a medication with a risk of retinal 
toxicity to the patients with optic neuritis. 
 
We acknowledge the retrospective nature of our cohort and likely bias by case 
severity as patients were included from two tertiary centres. Larger prospective 
longitudinal studies are now needed to confirm our observations and to 
establish whether the AQP4-Ab are persistent or transient and the effect of 
immunotherapy on these antibodies. In our study we used a qualitative assay 
for detection of anti AQP4-Ab; future studies using quantitative assays and 
temporal correlation with the clinical status would be of interest. Nevertheless, 
our results highlight that the association between jSLE and AQP4 autoimmunity 
and support the screening for these antibodies in all patients with jSLE to 
establish the risk of neurological involvement. 
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Table 1. Clinical and laboratory characteristics, imaging, treatment and follow up for the patients with jSLE and anti-AQP4 
antibody positivity. 
Patient ID, 
gender and 
ethnicity 
 
Age at 
onset 
(years
) 
Clinical features 
 
Ocular 
features 
Antibody profile Spine 
MRI 
Brain MRI CSF 
studies 
Treatment Disease 
course and 
imaging 
during follow 
up 
Follow-up 
(years) 
 
Patient 1 
Male, 
Afro-
Caribbean 
12  Arthritis 
 Pancytopenia with 
haematological picture 
of secondary 
macrophage activation 
syndrome 
 Lung vasculitis on 
biopsy, retinal 
vasculitis,  
 Psychotic episode with 
hallucinations 
 No focal neurological 
deficit 
Retinal 
vasculitis 
 ANA positive  
 Anti-dsDNA 
positive 
 Anti-C1q 
antibodies 
positive 
 Anti-ENA 
negative 
 AQP4-Ab positive 
 NMDAR-Ab 
negative 
 MOG-Abs 
negative 
 
Normal Long standing 
infarcts of right 
caudate 
nucleus and 
dorsal right 
lentiform 
nucleus 
 
Generalised 
progressive 
atrophy 
Not done  Induction: IVMP, 
Cyclophospham
ide, Rituximab; 
Etoposide 
 Maintenance 
therapy: 
Mycophenolate 
mofetil; 
hydroxychloroq
uine 
Disease 
controlled on 
medication, no 
evidence of 
clinical or 
radiological 
disease 
activity.  
 
 
 
3 
 
Patient 2 
Female, 
Afro-
Caribbean 
11  Malar rash 
 Raynaud phenomenon 
 Myositis 
 Lung involvement 
 Haematological 
disease (leukopenia, 
neutropenia) 
 Family history of SLE 
(father, paternal aunt) 
No  ANA positive 
 Anti ds-DNA 
negative 
 Anti-RNP positive 
 Anti-Ro positive 
 AQP4 positive 
 NMDAR-Ab 
negative 
 MOG-Abs 
negative 
 
LETM  Non-specific 
lesion 
subcortical 
frontal and 
parietal white 
matter  
 
Not done  Induction: 
Corticosteroids; 
Rituximab 
 Maintenance: 
Azathioprine; 
Methotrexate 
Persistent 
headaches but 
no further 
relapse with 
stable 
neuroimaging  
2 
 
Patient 3 
Female, 
Caucasian 
9  Non-specific gastro-
intestinal symptoms 
 Tubulo-interstitial 
nephritis on renal 
biopsy 
 Right sided 
monoparesis  
Unilateral 
optic atrophy 
diagnosed at 
2yrs 
 ANA positive 
 Anti-dsDNA 
weakly positive 
 Anti-RNP positive  
 Anti-Ro positive  
 AQP4-Ab positive 
 MOG-Ab negative 
LETM  
C3-T1 
central 
lesion  
 
Normal 
intracranial 
appearances 
Acelullar 
normal 
protein 
matched 
OCB 
 Induction: 
Corticosteroids, 
plasma 
exchange, 
cyclophosphami
de 
Five relapses 
with LETM  
 
Movement 
disorder  
 
 
9 
 ANA=antinuclear antibodies, dsDNA=double stranded DNA, ENA=extractable nuclear antigens, AQP4=aquaporin 4, 
IVMP=intravenous methylprednisolone, NMDA=N-methyl D-aspartate receptor, MOG=myelin oligodendrocyte glycoprotein, RNP 
=ribonucleoprotein, VGKC =voltage gated potassium channel, SLE=systemic lupus erythematosus, C=cervical vertebrae, T=thoracic 
vertebrae, EEG=electroencephalogram, MRI=magnetic resonance imaging, CSF=cerebrospinal fluid, LETM= Longitudinal extensive 
transverse myelitis, OCB=oligoclonal bands, IVIG=intravenous immunoglobulin  
 
 Unilateral optic atrophy 
(secondary to previous 
optic neuritis) 
  Maintenance: 
Azathioprine; 
Mycophenolate 
mofetil 
Patient 4 
Female, 
Asian 
10  Optic neuritis (ON) Four 
episodes of 
ON 
 ANA weakly 
positive 
 Anti-dsDNA 
positive 
 AQP4-Ab positive 
 MOG-Ab negative 
LETM  
C1-C5 
central 
lesion  
 
Abnormal 
signal right 
temporal cortex 
and amigdala 
and left 
thalamus and 
cervicomedulla
r junction.  
acelular 
normal 
protein 
OCB 
negative. 
 Induction:Cortic
osteroids 
 Maintenance:M
ethotrexate, 
Azathioprine 
Multiple 
relapses of 
optic neuritis 
and transverse 
myelitis. 
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Patient 5 
Female, 
Asian 
12 Acute onset  
 Vasculitic rash 
 Haematological 
disease with anaemia, 
lymphopenia, 
thrombocytopenia 
 Paresthesias with arms 
and legs weakness 
 Respiratory failure  
No  ANA positive 
 ENA screen 
positive, typing 
negative 
 AQP4-Ab positive 
 MOG-Ab negative  
 NMDAR Abs 
negative 
 
LETM  
C1-T1 
central 
lesion 
 
Single non-
specific white 
matter lesion in 
the right frontal 
lobe 
 
 
Not done  Induction: 
Corticosteroids, 
plasma 
exchange, IVIG   
 Maintenance: 
Rituximab 
Clinical 
improvement 
independently 
mobile. No 
clinical 
relapses  
 
1 
Drug doses: Corticosteroids= methylprednisolone given intravenous at 30 mg/kg/day for 3 consecutive days followed by oral 
prednisolone 1-2 mg/kg/day for 3-6 months; Azathioprine at 2 mg/kg/day; Rituximab intravenous given at two doses at 750 mg/m2  2 
weeks apart; Mycophenolate mophetil  at 600 mg/m2/day; intravenous Cyclophosphamide 4-6 doses at 500-750 mg/m2 given 
monthly; Subcutaneous Methotrexate  given at 15 mg/m2 once a week; Hydroxychloroquine at 6mg/kg/day: plasma exchange 2 
volume exchanges/day for 5-7 consecutive days. 
 Table 3. Predictors of presence of anti-Aq4 antibodies in patients with 
juvenile systemic lupus erythematosus jSLE. Groups were compared 
using Fisher’s exact test; p < 0.05 was considered significant.  
 
Features Anti-AQP4 
positive  
Anti-AQP4 
negative  
p-value 
Sex Male 1/11 (9.1%) 10/11 (90.9%) 0.487 
Female 4/79 (5.1%) 75/79 (94.9%) 
Clinical 
features 
Skin involvement Absent 3/17(17.6%) 14/17 (82.4%) 0.045 
Present 2/73 (2.7%) 71/73 (97.3%) 
Malar rash Absent 4/67 (6.0%) 63/67 (94.0%) 1.000 
Present 1/23 (4.3%) 22/23 (95.7%)  
Discoid rash Absent 5/87 (5.7%) 82/87 (94.3%) 1.000 
Present 0/3 (0%) 3/3 (100%)  
Photosensitivity Absent 5/78 (6.4%) 73/78 (93.6%) 1.000 
Present 0/12 (0%) 12/12 (100%)  
Mucocutaneous involvement Absent 3/63 (4.8%) 60/63 (95.2%) 0.634 
Present 2/27 (7.4%) 25/27 (92.6%)  
Oral ulcers Absent 4/64 (6.3%) 60/64 (93.8%) 1.000 
Present 1/26 (3.8%) 25/26 (96.2%)  
Musculoskeletal involvement Absent 2/18 (11.1%) 16/18 (88.9%) 0.260 
Present 3/72 (4.2%) 69/72 (95.8%)  
Arthritis Absent 3/56 (5.4%) 53/56 (94.6%) 1.000 
Present 2/34 (5.9%) 32/34 (94.1%)  
Serositis Absent 4/76 (5.3%) 72/76 (94.7%) 0.580 
Present 1/14 (7.1%) 13/14 (92.9%)  
Renal involvement Absent 4/62 (6.5%) 58/62 (93.5%) 1.000 
Present 1/28 (3.6%) 27/28 (96.4%)  
Neurological involvement Absent 0/62 (0%) 62/62 (100%) 0.002 
Present 5/28 (17.9%) 23/28 (82.1%)  
Haematological involvement Absent 3/54 (5.6%) 51/54 (94.4%) 1.000 
Present 2/36 (5.6%) 34/36 (94.4%)  
Lymphadenopathy Absent 4/81 (4.9%) 77/81 (95.1%) 0.417 
Present 1/9 (11.1%) 8/9 (88.9%)  
Laboratory 
results 
Anti double stranded DNA 
antibodies  
Negative 5/43 (11.6%) 38/43 (88.4%) 0.022 
Positive 0/47 (0%) 47/47 (100%)  
Anti-nuclear antibodies  Negative 1/12 (8.3%) 11/12 (91.7%) 0.520 
Positive 4/78 (5.1%) 74/78 (94.9%)  
Lupus anticoagulant Negative 4/82 (4.9%) 78/82 (95.1%) 1.000 
Positive 0/4 (0%) 4/4 (100%)  
Anti-cardiolipin antibodies Negative 5/86 (5.8%) 81/86 (94.2%) 1.000 
Positive 0/3 (0%) 3/3 (100%)  
Complement C3 levels Normal or high 5/73 (6.8%) 68/73 (93.2%) 0.579 
Low 0/17 (0%) 17/17 (100%)  
Antibodies to extractable nuclear 
antigens (ENA) 
Negative 2/35 (5.7%) 33/35 (94.3%) 1.000 
Positive 3/55 (5.5%) 52/55 (94.5%)  
ENA, anti-La/SSB  Negative 3/40 (7.5%) 37/40 (92.5%) 0.554 
Positive 0/15 (0%) 15/15 (100%)  
ENA, anti-RNP  Negative 1/20 (5%) 19/20 (95%) 1.000 
Positive 2/34 (5.9%) 32/34 (94.1%)  
ENA, anti-Ro/SSA  Negative 2/21 (9.5%) 19/21 (90.5%) 0.551 
Positive 1/34 (2.9%) 33/34 (97.1%)  
ENA, anti-Sm  Negative 3/41 (7.3%) 38/41 (92.7%) 0.562 
Positive 0/14 (0%) 14/14 (100%)  
Other ENA sub-type Negative 2/52 (3.8%) 50/52 (96.2%) 0.158 
Positive 1/3 (33.3%) 2/3 (66.7%)  
Treatment 
received 
Rituximab Not Prescribed 2/5 (40%) 55/85 (64.7%) 0.352 
Prescribed 3/5 (60%) 30/85 (35.3%) 
Cyclophosphamide Not Prescribed 3/5 (60%) 70/85 (82.4%) 0.237 
Prescribed 2/5 (40%) 15/85 (17.6%) 
Hydroxychloroquine Not Prescribed 3/5 (60%) 2/85 (2.4%) 0.001 
Prescribed 2/5 (40%) 83/85 (97.6%) 
Methotrexate Not Prescribed 3/5 (60%) 72/85 (84.7%) 0.192 
Prescribed 2/5 (40%) 13/85 (15.3%) 
Corticosteroids Not Prescribed 0/5 (0%) 42/85 (49.4%) 0.058 
Prescribed 5/5 (100%) 43/85 (50.6%) 
Azathioprine Not Prescribed 2/5 (40%) 56/85 (65.9%) 0.343 
Prescribed 3/5 (60%) 29/85 (34.1%) 
Mycophenolate Mofetil Not Prescribed 3/5 (60%) 54/85 (63.5%) 1.000 
Prescribed 2/5 (40%) 31/85 (36.5%) 
Other immunosuppressive agent Not Prescribed 4/5 (80%) 81/85 (95.3%) 0.254 
Prescribed 1/5 (20%) 4/85 (4.7%) 
Anti-coagulant drug Not Prescribed 3/5 (60%) 84/85 (98.8%) 0.007 
Prescribed 2/5 (40%) 1/85 (1.2%) 
Anti-hypertensive drug Not Prescribed 3/5 (60%) 64/85 (75.3%) 0.599 
Prescribed 2/5 (40%) 21/85 (24.7%) 
Aspirin Not Prescribed 5/5 (100%) 75/85 (88.2%) 1.000 
Prescribed 0/5 (0%) 10/85 (11.8%) 
Plasma exchange Not Undertaken 4/5 (80%) 84/85 (98.8%) 0.109 
Undertaken 1/5 (20%) 1/85 (1.2%) 
Anti-epileptics Not Prescribed 3/5 (60%) 82/85 (96.5%) 0.023 
Prescribed 2/5 (40%) 3/85 (3.5%) 
Anti-psychotics or anti-
depressants 
Not Prescribed 5/5 (100%) 80/85 (94.1%) 1.000 
Prescribed 0/5 (0%) 5/85 (5.9%) 
 
ANA=antinuclear antibodies, dsDNA=double stranded deoxyribonucleic acid, 
ENA=extractable nuclear antigens, AQP4=aquaporin 4, RNP 
=ribonucleoprotein, anti-Sm=anti-Smith antibodies, anti-Ro/SSA=anti Sjogren 
syndrome A antibodies, anti-La/SSB=anti Sjogren syndrome B antibodies  
 
 
 
 
